로딩 중…
StockDiggingStockDigging

KWANGDONG PHARMACEUTICAL CO.,LTD

009290· KOSPI
₩5,770-4.63%
2026-06-19

Price Chart

KWANGDONG PHARMACEUTICAL CO.,LTD-0.52%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap287.34B KRW
Revenue1.69T KRW
Net Income5.08B KRW
Total Assets1.32T KRW
Net Assets712.31B KRW
Employees1,072
Value
P/E56.58x
P/B0.40x
PEG1.84x
P/S0.17x
EV/EBITDA30.04x
FCF Yield19.89%
Profitability
ROE0.71%
ROA0.39%
Op. Margin2.08%
Revenue Growth8.81%
Earnings Growth30.74%
Financial Health
Debt Ratio185.09%
Total Debt306.19B KRW
FCF57.15B KRW
Cash96.62B KRW
Current Ratio1.30x
Net Debt/EBITDA12.67x
Dividend
Div. Yield1.65%
Div. Growth0.00%
Performance
1Y Return-0.52%
1M Return-18.50%
From 52W High-54.92%
1Y MDD-47.92%
Trading
Volume387,472 shares
Foreign Own.17.20%
Per Share
EPS417 KRW
BPS13,020 KRW

Company Info

CEO 최성원, 박상영(각자대표)
Employees 1,072
Founded 1963
HQ 경기도 과천시, KR
Website www.ekdp.com

Kwangdong Pharmaceutical, established in 1963 and headquartered in Gwacheon-si, Gyeonggi-do, secured domestic consignment sales rights for Samdasoo until 2029 through a re-contract with Jeju Development Corporation in 2025. The company operates a Pharmacy Business Division for traditional medicines like Ssanghwatang and Woohwangchungsimwon, and an ETC Business Division for specialized pharmaceuticals such as the anti-cancer drug Lenara and vascular fortifier Venitol. Its F&B Sales Division markets beverages like Vita500, Corn Silk Tea, Hogaengnamu Tea, and Jeju Samdasoo, solidifying its brand power in the pharmaceutical and food sectors.